All News
Filter News
Found 4,297 articles
-
GT Biopharma Inc. Announces Agreement with a Major Pharmaceutical Company to Study its Drug Candidate OXS-1550 in Combination With a Multi-Billion Dollar Oncology Drug
7/19/2018
GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) announced today a Material Transfer Agreement (MTA) between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota.
-
Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
7/12/2018
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial.
-
Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC
7/12/2018
Targovax and SOTIO announce the first patient has been dosed with ONCOS-102 in the SP015 phase I/II clinical trial in patients with prostate cancer, combining the Company's immune-priming adenovirus ONCOS-102, with SOTIO's DCVAC/PCa, an active cellular immunotherapy.
-
Otsuka Pharmaceutical to Acquire Visterra
7/11/2018
Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction.
-
Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
7/11/2018
Results of Combination “Triplet” of Tucatinib with Trastuzumab and Capecitabine Published in The Lancet Oncology
-
CORRECTING and REPLACING Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
7/11/2018
Results of Combination “Triplet” of Tucatinib with Trastuzumab and Capecitabine Published in The Lancet Oncology
-
Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
7/9/2018
Seattle Genetics, Inc., (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced completion of enrollment for the enfortumab vedotin EV-201 pivotal phase 2 clinical trial cohort of patients with locally advanced or metastatic urothelial cancer who have been previously treated with both platinum chemotherapy and a checkpoint inhibitor (PD-L1 or PD-1).
-
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
7/9/2018
First Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme
-
Cellerant Therapeutics, Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation for Romyelocel-L to Prevent Infections During Neutropenia
7/2/2018
RMAT designation confers similar advantages as breakthrough therapy designation.
-
TRIGR Therapeutics and ABL Bio Announce Global Oncology Collaboration on Pipeline of Next Generation Therapeutic Antibodies
7/2/2018
TRIGR Therapeutics and ABL Bio Corporation jointly announced today that it had entered into a binding agreement for TRIGR to license the global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer.
-
Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases
7/1/2018
Alteogen Inc. and Lynkogen Inc. announced that they have entered into an exclusive option agreement for the development of Alteogen’s novel GLP-1 mimetic and Alpha-1 Antitrypsin (A1AT) fusion proteins based on their proprietary NexPTM fusion technology to tackle NASH and metabolic diseases.
-
BioAtla Announces First Patient Treated In Phase1/2 BA3021-001 Clinical Trial For CAB-ROR2-ADC Therapeutic
6/28/2018
CAB-ROR2-ADC in clinical testing for treatment of several solid tumor types
-
NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S
6/28/2018
NBE Therapeutics AG, today announces a CHF 20 million extension of the Series B round.
-
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
6/28/2018
Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations Joe Petroziello (Juno Therapeutics) Appointed VP of Scientific & Corporate Communications
-
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific Officer
6/27/2018
Dr. Abbot brings extensive industry experience in the research, early product development and clinical translation of cell-based therapies.
-
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
6/18/2018
The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy.
-
Cellerant Therapeutics, Inc. Presents Phase 2 Results Showing CLT-008 Significantly Reduces Risk of Infections in AML Patients Undergoing Standard Induction Chemotherapy
6/18/2018
Cellerant Therapeutics, Inc. presented results from its randomized controlled Phase 2 clinical trial of CLT-008 (romyelocel-L, human myeloid progenitor cells), an off-the-shelf cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia.
-
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
6/13/2018
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial.
-
vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
6/12/2018
vTv Therapeutics Inc. today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints.
-
Zymeworks Closes Previously Announced Public Offering
6/11/2018
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares